NCT05109234View on ClinicalTrials.gov

A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

PHASE3CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

March 30, 2022

Primary Completion Date

March 18, 2025

Study Completion Date

March 18, 2025

Conditions
Childhood Absence EpilepsyJuvenile Absence Epilepsy
Interventions
DRUG

Brivaracetam Film-coated tablet

"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Brivaracetam film-coated tablet \[10, 25 or 50 mg\] will be administered twice per day in equal doses."

DRUG

Brivaracetam oral solution

"* Pharmaceutical form: Oral solution~* Route of administration: Oral use~Brivaracetam oral solution \[10 mg/mL\]) will be administered twice per day in equal doses."

Trial Locations (24)

27157

Ep0132 109, Winston-Salem

30912

Ep0132 110, Augusta

35233

Ep0132 115, Birmingham

92868-3874

Ep0132 105, Orange

08901

Ep0132 100, New Brunswick

Unknown

Ep0132 400, Tbilisi

Ep0132 401, Tbilisi

Ep0132 402, Tbilisi

Ep0132 403, Tbilisi

Ep0132 405, Tbilisi

Ep0132 323, Messina

Ep0132 321, Milan

Ep0132 320, Pavia

Ep0132 322, Roma

Ep0132 325, Roma

Ep0132 326, Verona

Ep0132 562, Bucharest

Ep0132 560, Iași

Ep0132 561, Timişoara, Judeţ Timiş

Ep0132 632, Bardejov

Ep0132 630, Dubnica nad Váhom

Ep0132 600, Dnipro

Ep0132 601, Dnipro

Ep0132 607, Uzhhorod

All Listed Sponsors
lead

UCB Biopharma SRL

INDUSTRY